Cargando…

Study on the Relationship Between PTPRO Methylation in Plasma and Efficacy Neoadjuvant Chemotherapy in Patients with Early Breast Cancer

OBJECTIVE: This study aimed to explore the correlation between PTPRO methylation in plasma and the efficacy of neoadjuvant chemotherapy (NAC) for early breast cancer (BC). METHODS: Eighty-two patients with early BC undergoing NAC were included. PTPRO methylation status in plasma before and after NAC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiang-Wei, Hong, Mei-Juan, Qu, Yan-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627070/ https://www.ncbi.nlm.nih.gov/pubmed/37937223 http://dx.doi.org/10.2147/IJWH.S428038

Ejemplares similares

PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis
por: Zhang, Wenjie, et al.
Publicado: (2015)

Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients
por: Li, Shao-ying, et al.
Publicado: (2014)

PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy
por: Huang, Yi-Teng, et al.
Publicado: (2013)

Comprehensively Analyze the Prognosis Significance and Immune Implication of PTPRO in Lung Adenocarcinoma
por: Lin, Zhimin, et al.
Publicado: (2023)

PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism
por: Dai, Weixing, et al.
Publicado: (2022)

Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment
por: Yao, Zhimeng, et al.
Publicado: (2023)

PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2
por: Dong, H, et al.
Publicado: (2017)

PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer
por: Hou, Xuben, et al.
Publicado: (2021)

PTPRO-related CD8(+) T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer
por: Dong, Hongmei, et al.
Publicado: (2022)

Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Wang, Huan, et al.
Publicado: (2020)

Association between the methylation status of PCDH17 and the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer
por: Kong, De-Di, et al.
Publicado: (2020)

Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance
por: Dong, Hongmei, et al.
Publicado: (2022)

The Effect of the Leptin and Leptin Receptor Expression on the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Kong, Yan, et al.
Publicado: (2019)

Efficacy Evaluation of Neoadjuvant Chemotherapy in Breast Cancer by MRI
por: Liu, Yongguang, et al.
Publicado: (2022)

ABVS-Based Radiomics for Early Predicting the Efficacy of Neoadjuvant Chemotherapy in Patients with Breast Cancers
por: Jiang, Wei, et al.
Publicado: (2023)

Neoadjuvant chemotherapy: practice and thinking for Chinese patients with early breast cancer
por: Wang, Xue-Fei, et al.
Publicado: (2020)

Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Kong, Xianshu, et al.
Publicado: (2022)

Early prediction of response to neoadjuvant chemotherapy using contrast-enhanced ultrasound in breast cancer
por: Peng, Juan, et al.
Publicado: (2021)

Association between the nucleosome footprint of plasma DNA and neoadjuvant chemotherapy response for breast cancer
por: Yang, Xu, et al.
Publicado: (2021)

The Plasma Concentration of D-Dimer is Associated with Neoadjuvant-Chemotherapy Efficacy and the Prognosis in Osteosarcoma
por: Huang, Yujing, et al.
Publicado: (2021)

Correlation Between Immune-Related Genes and Tumor-Infiltrating Immune Cells With the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Zhou, Yan, et al.
Publicado: (2022)

Monitoring early responses to neoadjuvant chemotherapy and the factors affecting neoadjuvant chemotherapy responses in primary osteosarcoma
por: Yu, Hong, et al.
Publicado: (2023)

Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer
por: Leone, José Pablo, et al.
Publicado: (2022)

CRYP-2/cPTPRO is a neurite inhibitory repulsive guidance cue for retinal neurons in vitro
por: Stepanek, Laurie, et al.
Publicado: (2001)

PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma
por: Gan, Jinfeng, et al.
Publicado: (2020)

DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival
por: Pedersen, Christine Aaserød, et al.
Publicado: (2022)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Liang, Hongling, et al.
Publicado: (2021)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress
por: Chen, Yushi, et al.
Publicado: (2023)

Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer
por: Bayarmaa, Battseren, et al.
Publicado: (2019)

Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma
por: Ming, Fei, et al.
Publicado: (2017)

MiR-6869-5p Induces M2 Polarization by Regulating PTPRO in Gestational Diabetes Mellitus
por: Wang, Pingping, et al.
Publicado: (2021)

The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer
por: Beresford, M J, et al.
Publicado: (2006)

PTPRO knockdown protects against inflammation in hemorrhage shock-induced lung injury involving the NF-κB signaling pathway
por: Huan, Zhirong, et al.
Publicado: (2022)

Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy
por: Sakaguchi, Asumi, et al.
Publicado: (2021)

Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Gwark, Sungchan, et al.
Publicado: (2021)

The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis
por: Zhang, Wei, et al.
Publicado: (2017)

Association of T-cadherin levels with the response to neoadjuvant chemotherapy in locally advanced breast cancer
por: Kong, Dedi, et al.
Publicado: (2017)

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alba, Emilio, et al.
Publicado: (2016)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_mhaleqi5bc4p8g3dr0cdfa34l4